Session Detail


Session Title: Phase II/III Clinical Trials
Session Type: Poster Session
Session Start/End Time: Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Location: Hall A-E, Poster Section 38
CME: (not eligible for CME credit)
Session Category: Clinical Trials 2
Presentations:
CT301: Late disease recurrence in estrogen receptor positive (ER+) premenopausal breast cancer (BC)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Francesco Recchia1, Giampiero Candeloro1, Stefano Necozione2, Silvio Rea3, William Soo Hoo4, Tom Cantor4. 1Civilian Hospital, Avezzano, Italy; 2University Department of Life, Health and Environmental Sciences, L'Aquila, Italy; 3University Department of Biotechnological and Applied Clinical Sciences, L'Aquila, Italy; 4Scantibodies Laboratory, Inc, San Diego, CA
CT302: A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Stacy Cowherd1, Susan Melin1, Steven Akman2, John Cole3, Julia Lawrence1. 1Wake Forest University Baptist Medical Center, Winston Salem, NC; 2Roper Saint Francis, Charleston, SC; 3Ochsner Medical Center, New Orleans, LA
CT303: A multicenter phase ii study of adjuvant chemotherapy with oral fluoropyrimidine s-1 for non-small-cell lung cancer
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Tomoshi Tsuchiya, Naoya Yamasaki, Keitaro Matsumoto, Takuro Miyazaki, Takeshi Nagayasu. Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
CT304: Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Yulian Khagi, Gurveen Kaur, Paul Christos, Naveed H. Akhtar, David M. Nanus, Neil H. Bander, Scott T. Tagawa. Weill Cornell Medical College, New York, NY
CT306: Breast cancer chemoprevention by IGF-I inhibition in women with atypical hyperplasia of the breast: A phase 1/2 proof of principle trial
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
David L. Kleinberg1, Deborah Axelrod1, Julia Smith1, Baljit Singh1, Martin Lesser2, Pietro Ameri1, Ann Danoff1, Irineu Illa Bochaca1, Cristina de Angelis1. 1New York University School of Medicine, New York, NY; 2Feinstein Institute for Medical Research, Manhasset, NY
CT307: Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Naval Daver1, Hagop M. Kantarjian1, Guillermo Garcia - Manero1, Naveen Pemmaraju1, Tapan Kadia1, Courtney DiNardo1, Nitin Jain1, Gautum Borthakur1, Jorge Cortes1, Craig Adam2, Farhad Ravandi1. 1UT MD Anderson Cancer Ctr., Houston, TX; 2Sunesis Pharmaceuticals, Inc., San Francisco, CA
CT308: Pre-surgical statin-treatment in a window-of-opportunity breast cancer trial: Changes in gene expression profiles.
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Olof Bjarnadottir1, Ida Johansson1, Srinivas Veerla2, Karin Jirstrom3, Dorthe Grabau3, Ingrid Hedenfalk1, Signe Borgquist1. 1Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; 2SCIBLU genomics; Lund University, Lund, Sweden; 3Division of Pathology, Lund University, Lund, Sweden
CT309: Influencing the tumor microenvironment: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Nancy Chan, Naomi Kornhauser, Maureen Ward, Amy Willis, Tessa Cigler, Ellen Chuang, Anne Moore, Diana Donovan, Sarah E. Schneider, Christina Lam, David J. Warren, Anna Rubinchik, Sandra Hurtado Rua, Sharrell Lee, Maureen Lane, Vivek Mittal, Linda Vahdat. New York Presbyterian Weill Cornell, New York, NY
CT310: Molecular correlates of activity and survival in a phase I/II trial of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Bishoy Faltas, Gurveen Kaur, Naveed Akhtar, Paul Christos, Brian Robinson, Beerinder Singh, Himisha Beltran, David Nanus, Scott T. Tagawa. Weill-Cornell Medical College, New York, NY
CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Ana B. Oton1, Byoung Chul Cho2, Myung-Ju Ahn3, Sang-We Kim4, Kirushnakumar Subramanian5, Chirag Desai6, Dale Shuster7, Terri Goldberg7, Hamim Zahir7, Dipen Dutta7, Shuquan Chen7, Richard Von Roemeling7, Joachim von Pawel8. 1University of Colorado Denver, Denver, CO; 2Severance Hospital, Korea, Republic of; 3Samsung Medical Center, Korea, Republic of; 4Asan Medical Center, Korea, Republic of; 5Meenakshi Mission Hospital, India; 6Hemato Oncology Clinic (P) Ltd., India; 7Daiichi Sankyo Pharma Development, NJ; 8Asklepios Fachkliniken München-Gauting, Gauting, Germany
CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Cristina Papayannidis1, Caterina De Benedittis1, Simona Soverini1, Ilaria Iacobucci1, Maria Chiara Abbenante1, Chiara Sartor1, Maria Teresa Bochicchio1, Anna Ferrari1, Claudia Venturi1, Valentina Robustelli1, Andrea Ghelli Luserna di Rorà1, Viviana Guadagnuolo1, Emanuela Ottaviani1, Nicoletta Testoni1, Carmen Baldazzi1, Simona Luatti1, Sarah Parisi1, Stefania Paolini1, Alberto Conficoni1, Federica Frabetti1, Elisa Lani1, Silvia Piccari1, Paolo Di Bartolomeo2, Roberto Di Lorenzo2, Renato Fanin3, Giuseppe Cimino4, Fabio Ciceri5, Giovanni Martinelli1. 1Inst. of Hematology "L. e A. Seràgnoli", Univ. of Bologna, Bologna, Italy; 2U.O. Hematology, Pescara, Italy; 3U.O. Hematology, Udine, Udine, Italy; 4Hematology, Sapienza University, Rome, Italy; 5U.O. Hematology, San Raffaele Hospital, Milan, Milan, Italy
CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Eleni Efstathiou1, Hari Deshpande2, Daniel George3, Anthony M. Joshua4, Mary-Ellen Taplin5, Thomas W. Griffin6, Anil Londhe7, Mary Todd8, Arturo Molina9. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Yale University Cancer Center, New Haven, CT; 3Duke University Medical Center, Durham, NC; 4Princess Margaret Cancer Center, Toronto, ON, Canada; 5Dana-Farber Cancer Institute, Boston, MA; 6Janssen Research & Development, Los Angeles, CA; 7Janssen Research & Development, Horsham, PA; 8Janssen Global Services, Raritan, NJ; 9Janssen Research & Development, Menlo Park, CA
CT314: "Multi-metronomic" algorithms for targeted therapy to improve value of response and "failed drugs" for "resistant" women's cancers
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Howard W. Bruckner1, Azriel Hirschfeld2, Jeanetta Stega3, Peter Dottino4. 1MZB Foundation for Cancer Research, New York, NY; 2Bruckner Oncology, Bronx, NY; 3Luminant Biosciences, West Caldwell, NJ; 4Mount Sinai Medical Center, New York, NY
CT315: IG-002 Phase 3 data: Absence of correlation between unbound paclitaxel and response in MBC
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Monica Choi, Jeff Hsu, Vuong Trieu. Sorrento Therapeutics Inc., Irvine, CA
CT316: IG-001 phase 4 data in Korea: Safety and efficacy
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Larn Hwang, Caleigh Douglass, David Nam, Vuong Trieu. Sorrento Therapeutics Inc., Irvine, CA
CT317: CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with TDM1
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
François-Clément Bidard, Yann de Rycke, Bernard Asselain, Paul Cottu, Manuel Rodrigues, Ronald Lebofsky, Jean-Yves Pierga. Inst. Curie, Paris, France
CT318: FOLFOXIRI+B-mab showed powerful effect as preoperative chemotherapy for multiple liver metastases of colorectal cancer
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Yasushi Ichikawa, Ayumu Goto, Noritoshi Kobayashi, Motohiko Tokuhisa, Takashi Ishikawa, Atsushi Ishibe, Kazuteru Watanabe, Kazunori Nojiri, Yoshibumi Kumamoto, kazuhisa Takeda, Mitsuyoshi Ota, Hirotoshi Akiyama, Kuniya Tanaka, Itaru Endo. Yokohama City Univ, Yokohama, Japan
CT319: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Polly A. Niravath, Sue Hilsenbeck, Tao Wang, Mothaffar Rimawi. Baylor College of Medicine, Houston, TX
CT320: Longitudinal observational study to simultaneously evaluate multiple blood-based biomarkers to track the emergence of metastasis and drug resistance in colorectal cancer
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Clarinda Chua, Rachel Ten, Thinzar Aung, Maricel Ang, Thein Htut Oo, Su Pin Choo, Matthew Ng, Iain Beehuat Tan. National Cancer Centre Singapore, Singapore
CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Geeta Gulati1, Siri Lagethon Heck1, Anne Hansen Ree1, Åse Bratland2, Kjetil Steine1, Jeanette Schulz-Menger3, Berit Gravdehaug4, Pavel Hoffmann5, Helge Røsjø1, Jürgen Geisler1, Torbjørn Omland1. 1Akershus University Hospital and University of Oslo, Lørenskog and Oslo, Norway; 2Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway; 3Charitè/HELIOS, Berlin, Germany; 4Akershus University Hospital, Lørenskog, Norway; 5Oslo University Hospital, Ullevål, Oslo, Norway
CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Nicholas J. Robert1, Veronique Dieras2, Christian Jackisch3, Stefanie Srock4, Ulrich Freudensprung5, Leonardo Faoro6, Joyce O’Shaughnessy7. 1Virginia Cancer Specialists, US Oncology, Fairfax, VA; 2Institut Curie, Paris, France; 3Klinikum Offenbach, Offenbach, Germany; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland; 5Stamford Consultants AG, Basel, Switzerland; 6Genentech, Inc, South San Francisco, CA; 7Baylor-Sammons Cancer Center and Texas Oncology, US Oncology, Dallas, TX
CT323: Pemetrexed versus docetaxel in patients with EGFR-mutant lung adenocarcinoma previously treated with epidermal growth factor receptor tyrosine kinase inhibitors
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM
Kim Kyu-Sik, Bo Ram Lee, Sung Hoon Yoon, Jinyeong Yu, Injae Oh, Young Chul Kim, Sangyun Song, Yooduk Choi, Hee Jung Ban. Chonnam National University Hwasun Hospital, Hwasun-eup, Hwasun-gun, Jeollanam-do, Korea, Republic of